Prothena Corporation plc Logo

Email this page: News Release

Prothena's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses in Ongoing Phase 1 Study in Patients With Immunoglobulin Light Chain (AL) Amyloidosis

For security reasons, registration is required before you can use this feature.
* Indicates required field